Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Safinamide mesylate by Zambon Co for Drug-Induced Dyskinesia: Likelihood of Approval
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia. According to GlobalData,...
Data Insights
Safinamide mesylate by Zambon Co for Drug-Induced Dyskinesia: Likelihood of Approval
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia. According to GlobalData,...